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PI 3-kinase puts GTP on the Rac
Phosphoinositide 3-kinase, an enzyme that is known to transduce signals
received by a variety of receptor types, has been found to mediate agonist-
dependent membrane ruffling via the small GTP-binding protein Rac.
It is invariably satisfying to see connections made between
hitherto unlinked components of signal transduction path-
ways. This is particularly true when the two components
carry with them a large literary baggage; the consequence
is often that a lot of previously purely descriptive results
begin to make mechanistic sense. In a paper that appeared
recently in Current Biology [1], Hawkins and colleagues
have drawn together two such disparate strands to provide
the basis for a molecular description of the mechanisms
responsible for the agonist control of a well-described
eukaryotic cellular phenomenon - membrane ruffling.
The characters involved in this plot are a lipid kinase -
phosphoinositide 3-kinase (PI 3-kinase) - and the small
GTP-binding protein Rac. Why is there such interest in
PI 3-kinase? As its name implies, PI 3-kinase catalyzes the
phosphorylation of the inositol ring of its lipid substrate
at the 3-OH position (see Fig. 1). Thus, in contrast to
the classical pathway of signal-dependent inositol lipid
hydrolysis - in which activated phospholipase C releases
the two signalling molecules inositol 1,4,5-trisphosphate
(IP 3) and diacylglycerol (DAG) - PI 3-kinase generates
the highly phosphorylated lipid, phosphoinositide
3,4,5-trisphosphate (PIP 3). PI 3-kinase can also generate
PIP and PIP 2 - from substrates PI and PIP, respectively
- but labelling studies [2] suggest that PIP 3 is the
important signal-generated product.
PI3-kinase was originally identified in association with
particular activated receptor tyrosine kinase complexes
[3,4], and it has subsequently been found in many others
(reviewed in [5]). The enzyme was found to consist of
two subunits: an 85 kD regulatory subunit, with two 'Src
homology 2' (SH2) domains, and a 110 kD catalytic sub-
unit [6] which shows homology to a yeast vacuolar pro-
tein sorting gene product (VP34p, which does indeed
possess PI 3-kinase activity [7]). The two SH2 domains of
the 85 kD regulatory subunit enable it to bind tyrosine-
phosphorylated sequences within the cytosolic domains
of receptor tyrosine kinases, explaining how PI 3-kinase
becomes assembled on activated, autophosphorylated,
receptor tyrosine kinase complexes.
The activation of p85/p110 PI 3-kinase that is conse-
quent on ligand stimulation of a receptor tyrosine kinase
is likely to be due to a combination of factors. These are,
first, binding of the enzyme to the tyrosine phosphory-
lated target motif (the peptide YMXM, in the single-
letter amino-acid code); second, the fact that complex
assembly occurs at the membrane, thus bringing the
enzyme in close proximity with its lipid substrate; and
third, direct interaction of the enzyme with the small
GTP-binding protein Ras [8,9]. Activation of PI
3-kinase leads to production of PIP 3, but how is the signal
transmitted downstream of this lipid metabolite?
Fig. 1. Two pathways from phosphatidylinositol are important in the generation of intracellular signalling molecules. The pathways
diverge at PIP2: PI 3-kinase catalyzes phosphorylation of this lipid, generating PIP3; phospholipase C (PLC) catalyzes hydrolysis of PIP2,generating IP3, which activates release of Ca2+ from internal stores, and diacylglycerol (DAG), which activates protein kinase C.
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The recent advances in understanding the role of PI
3-kinase as an upstream element in an important intracel-
lular signalling pathway have in large part been made
possible by the availability of a specific inhibitor of the
enzyme, the anti-fungal agent wortmannin. This, and
certain related compounds, have been shown to inhibit
PI 3-kinase with great potency (Ki 10 nM), both in
vitro and in vivo [10,11]. At higher concentrations of
wortmannin, other proteins are also affected, but to date
PI 3-kinase is the only known high-affinity target in
mammalian cells. Wortmannin inhibits a number of cel-
lular responses, in particular the activation of neutrophils,
suggesting that PI 3-kinase is a component of the intra-
cellular signalling pathways that mediate these responses.
Of particular relevance for the recent work of Hawkins et
al. [1] - discussed in more detail below - wortmannin
has been shown to inhibit the membrane ruffling response
of cells that is observed following stimulation with certain
agonists [12,13]. Indeed, in the course of their recent study,
Hawkins et al. [1] have shown that, in porcine aortic
endothelial cells, the ruffling response to platelet-derivied
growth factor (PDGF) is blocked not only by wortmannin,
but also by a mutant form of the p85 subunit of PI 3-kinase
that does not bind to the p1 10 catalytic subunit to direct
its activation. This observation brings us to the second
character in the story, the small GTP-binding protein Rac.
The family of small GTP-binding proteins encompasses
four classes, namely the Ras, Rho (which includes Rac),
Rab and ARF (ADP-ribosylation factor) families. Each
class, broadly speaking, appears to be involved in a partic-
ular area of cell biology. Thus, Ras family proteins can
regulate various growth responses [14], Rab family pro-
teins regulate vesicle sorting pathways [15], and ARF,
which is also involved in vesicle traffic, has recently been
implicated in the control of phospholipase D [16]. In
each of these contexts, the loading of the GTP-binding
protein with GTP catalyzed by a GTP-GDP exchange
protein is the critical first step in its cyclical action.
The active, GTP-bound protein subsequently interacts
with its target 'effector' proteins, the activities of which
are modified as a result of the interaction. The GTP-
bound protein reverts to the inactive state on GTP
hydrolysis, promoted either by a specific GTPase-
activating protein (GAP) or by the interaction with the
target protein itself. So where does the Rho family fit
in? Seminal work from Ridley, Hall and colleagues (see
[17,18]) has shown that members of this family -
Cdc42, Rho and Rac - are regulators of the actin
cytoskeleton. For example, microinjection of GTP-
bound Rho has been shown to induce actin stress fibres
in fibroblasts. Similarly, microinjection of active Rac will
induce a reorganization of the membrane-associated actin
cytoskeleton - the cortical cytoskeleton - producing a
characteristic membrane ruffling response.
So, PI 3-kinase and Rac are connected by their involve-
ment in the control of membrane ruffling. Hawkins et. al.
[1] have now provided evidence that these two elements
operate in a hierarchy, wherein activated PI 3-kinase
increases the level of the GTP-bound, active form of
Rac, which in turn induces the changes in the actin
cytoskeleton responsible for membrane ruffling (Fig. 2).
The first line of evidence for this comes from the experi-
ments with inhibitors alluded to above. Thus, they found
that treatments that inhibit PI 3-kinase - wortmannin
and the dominant-negative mutant form of p85 - block
membrane ruffling that is normally induced in an
endothelial cell line by PDGF; these treatments did not,
however, block membrane ruffling induced directly by
injection of a constitutively active mutant form of Rac.
The second line of evidence comes from direct measure-
ments of the level of GTP loading on Rac in vivo. The
ratio of GDP:GTP bound forms of Rac is determined by
the rate of nucleotide (GTP for GDP) exchange and the
rate of hydrolysis of Rac-bound GTP. Unlike the situation
with Ras, with Rac it had previously been impossible to
determine the ratio of bound GDP:GTP in vivo (the req-
uisite antibodies not being available). To circumvent this
obstacle, stable cell lines were established expressing an
epitope-tagged form of Rac that permits immunoisola-
tion from cells (control or stimulated) and determination
of the GDP:GTP ratio. PDGF was found to increase the
GTP-Rac level 1.7-fold, and this effect is blocked by the
PI 3-kinase inhibitor wortmannin. Interestingly, this
increase was found to result from the combination of a
Fig. 2. PDGF receptor coupling to actin polymerization. The acti-
vated, tyrosine-autophosphorylated PDGF receptor is shown
interacting with the heterodimeric PI 3-kinase (p85/p110). The
consequent activation leads to PIP3 production, which is in turn
responsible for causing GDP-Rac to dissociate from its binding
protein GDI (for 'guanine nucleotide dissociation inhibitor')
and/or exchange GDP for GTP, releasing GTP-Rac, which some-
how stimulates actin polymerization. A second PDGF-receptor-
dependent, P 3-kinase-independent, pathway, mediated by a
putative transducing component 'X', amplifies the response by
inhibiting Rac GTPase activity (which is itself stimulated by GAP).
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wortmannin-sensitive increase in GTP-GDP exchange
on Rac, and a wortmannin-insensitive decrease in Rac
GTPase activity (Fig. 2). The central conclusion, then, is
that PDGF, by activating the PI 3-kinase, causes an
increase in the level of GTP-Rac, which in turn controls
actin polymerization and hence membrane ruffling.
Is Rac activation the sole result of PI 3-kinase action?
The ability of wortmannin to block other responses sug-
gests not. For example, wortmannin has been shown to
block up-regulation of the glucose transporter GLUT4
in pancreatic islet cells in response to insulin [19].
Although PDGF and insulin can both induce a robust
activation of PI 3-kinase, only insulin can induce
GLUT4 up-regulation. This distinction appears to reflect
the differential localization of the activated PI 3-kinase (P.
Shepherd and K. Siddle, personal communication) and
the consequent compartmentalized nature of the lipid
product, PIP 3. Unlike second messengers such as cAMP,
which are free to diffuse as water-soluble entities, lipid
messengers are largely restricted to the membrane com-
partments in which they are made, at least until that
compartment buds from, or fuses with, another. Thus,
activation of PI 3-kinases in distinct locations may have
profoundly different consequences. A further potential
source of diversity is the existence of multiple, distinct PI
3-kinases, though whether this is relevant to the selective
responsiveness of islet cells is not known.
Another pathway, involving the activation of the
p7OS6kinase, does, however, appear to involve a distinct,
but related, PI 3-kinase. This signalling event is sensitive
to the immunosupressive drug rapamycin, which has
been shown [20] to interact in the yeast Saccharomyces
cerevisiae with two gene products, TOR1 and TOR2,
that encode PI 3-kinase-related proteins. Rapamycin
does not inhibit the p85/pl O10 PI 3-kinase, but in mam-
malian cells it does inhibit p7 0S6kinase activation [21],
implying the existence of a distinct agonist-regulated
PI3-kinase signalling pathway. At least two further PI
3-kinase activities have been identified, one regulated by
seven-transmembrane-helix receptors via heterotrimeric
G protein 3y subunits [22], and one that shows a speci-
ficity for the lipid PI -as opposed to PIP 2 - as sub-
strate [23]. This suggests that the compartmentalization
afforded by the lipid products of these distinct activities
may be involved in a variety of cellular control processes.
Although the plethora of events known to involve PI
3-kinases is still growing, no others have been connected
in the manner described by Hawkins et al. [1] for Rac
activation. Inevitably, then, this system will be fertile
ground for further dissection. How the increase in
GTP-GDP exchange on Rac is effected, and the means
by which GTP-Rac controls local actin polymerization
are evidently crucial outstanding issues. Perhaps the most
intriguing question, however, is whether the results of
Hawkins et al. have revealed a general principle of PI
3-kinase action - are all the responses to PI 3-kinase
mediated via GTP-binding proteins?
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